Atrial Fibrillation
Conditions
Brief summary
To assess the acute efficacy of ablation of the most stable VX1 areas (levels 2 and 3) in terms of the rate of acute AF termination. Identify the spatial distribution of dispersion stability levels based on VX1. Document the rate of adverse events. To assess the long-term efficacy of ablation of the most stable VX1 areas in terms of the absence of documented arrhythmias during a 12-month follow-up.
Interventions
PROCEDUREAF ablation
AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability).
Sponsors
Hospital St. Joseph, Marseille, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients 18 years of age or older candidates with Persistent or long-standing persistent AF with documentation of (ECG, Holter, physician's letter): * AF duration of ≥ 3 months and ≤ 5 years or * 1 effective cardioversion followed by AF recurrence lasting ≥ 3 months 2. Continuous anticoagulation with warfarin (INR 2-3) or NOAC for \> 4 weeks prior to ablation 3. Patients must be able and willing to provide written informed consent to participate in the clinical trial 4. Maximum of 50% of patients (13 patients) in persistent AF \< 12 months (\>30% of long-standing persistent AF ≥ 12 months) 5. Being affiliated to a social security scheme or beneficiary of such a scheme
Exclusion criteria
1. Paroxysmal and short-standing persistent AF \< 3 months 2. Severe obesity (BMI \> 45) 3. LA thrombus on Transesophageal Echocardiography (TEE) prior to procedure 4. Contraindications to anticoagulation (heparin, warfarin or NOAC) 5. Patients who are or may potentially be pregnant 6. Any cardiac surgery within the past 2 months (60 days) (includes PCI) 7. Myocardial infarction within the past 2 months (60 days) 8. History of blood clotting or bleeding abnormalities 9. Documented thromboembolic event (including TIA) within the past 12 months (365 days) 10. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days) 11. Unstable angina within the past month 12. Acute illness or active systemic infection or sepsis (including COVID 19) 13. Enrollment in an investigational study evaluating another device, biologic, or drug 14. Presence of intramural thrombus, tumor or other abnormality or condition that precludes vascular access, or manipulation of the catheter 15. Life expectancy or other disease processes likely to limit survival to less than 12 monthsLife expectancy or other disease processes likely to limit survival to less than 12 months 16. Acute Covid-19 infection (fever and/or biological inflammatory syndrome, and positive test documented) 17. Patient protected (guardianship or curatorship), or deprived of liberty by a judicial or administrative decision; 18. Person subject to a safeguard measure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AF termination rate after ablation of the most stable regions (levels 3 and 2) | at the end of the procedure | sinus rhythm at the end of the procedure |
Countries
France
Outcome results
None listed